NCT02925351

Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Jonsson Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan may help to determine how fluorine F 18 clofarabine is distributed throughout the body.

Detailed description

PRIMARY OBJECTIVES: I. Determine how fluorine F 18 clofarabine (18F-clofarabine) is distributed in the body, in patients with autoimmune and inflammatory diseases. II. Determine whether 18F-clofarabine can be used to image patients with autoimmune and inflammatory diseases. OUTLINE: Patients receive fluorine F 18 clofarabine intravenously (IV) and undergo a single PET/CT scan for up to 120 minutes.

Conditions

• Autoimmune Disease
• Crohn Disease
• Inflammatory Disorder
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Takayasu Arteritis

Interventions

Type	Name	Description
PROCEDURE	Computed Tomography	Undergo PET/CT scan
RADIATION	Fluorine F 18 Clofarabine	Given IV
PROCEDURE	Positron Emission Tomography	Undergo PET/CT scan

Timeline

• Start date: 2016-01-25
• Primary completion: 2018-04-30
• Completion: 2018-04-30
• First posted: 2016-10-05
• Last updated: 2020-09-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study